eyonis LCS study results to be presented at CHEST 2026: what it means
A study from eyonis Inc., a Median Technologies company, plans to present results at CHEST 2026 about the performance of eyonis LCS, an AI-based software tool used in lung cancer screening. The company says the study reports high sensitivity, specificity, and negative predictive value, which are technical ways to measure how well a test detects cancer and correctly identifies non-cases. The event is focused on pulmonologists and other clinicians who use imaging to screen for lung cancer.
What the study claims
The press release describes results for eyonis LCS, described as AI/ML-based software that combines computer-aided detection and diagnosis for lung cancer screening. The company reports 93.3% sensitivity (the ability to detect true cancer cases), 92.4% specificity (the ability to correctly identify people without cancer). 99.9% negative predictive value (the likelihood that a person flagged as not having cancer truly doesn’t have it). The claim asserts this as performance data for their tool in lung cancer screening contexts.
Key facts about the tool and event
Eyonis LCS is described as the first and only FDA-cleared AI/ML-based software for both detection and diagnosis in lung cancer screening. The CHEST 2026 meeting is a major industry conference where pulmonologists discuss advances in chest medicine. The press release indicates the company will present at CHEST 2026 in Phoenix, Arizona, between October 18–21, 2026.
Who is affected
Clinicians who perform lung cancer screening using imaging and AI decision-support tools may be influenced by these results. If the data hold up under peer review, pulmonologists and radiologists could consider eyonis LCS as part of screening workflows. Patients undergoing lung cancer screening might be directly affected in terms of how scans are interpreted and how decisions about follow-up tests are made.
Practical next steps for readers
If you are a clinician: monitor CHEST 2026 coverage and the full study publication for validation, methods, and context. Consider how a high sensitivity and specificity tool would fit into your screening protocol and how it would affect patient communication about results. If you are a patient: discuss screening results and any AI-assisted interpretations with your healthcare provider, and ask how decisions would change with this tool.
Limits and questions to consider
The summary numbers come from a press release; details such as study design, sample size, population, and whether the data underwent independent peer review are not provided here. Without those details, readers should be cautious about generalizing the results to all settings or populations. The phrasing “FDA-cleared” refers to clearance status but does not replace the need for published peer-reviewed evidence and real-world performance data.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- biospace.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.